Articles On CogState (ASX:CGS)

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The life s...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Brad O’Connor, managing director and C...

Neuroscience tech company Cogstate (ASX:CGS) produced some much needed good news today, saying it has executed $9.1m of clinical trials sales contracts since the start of 2020. The stock — up about 30 per cent on the news — says this revenu...

Dementia already affects hundreds of thousands of people in Australia, and it’s only going to get worse if a medical miracle is not forthcoming. The term relates to brain diseases, including Alzheimers, that impact a person’s ability to thi...

You may have heard the saying “it’s not brain surgery” in the context of trying to prove something easy. Well there is a reason  — our brains are among the most difficult parts of our body to treat. There are a few ASX small caps trying to...

Australia’s S&P/ASX 200 (Index: ^AXJO)(ASX: XJO) and ALL ORDINARIES (Index: ^AXAO) (ASX: XAO) indices finished lower on Friday. Here’s a short recap of the Australian market: S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) lower 0.16% to 6...

The CogState Limited (ASX: CGS) share price surged after the brain health testing company reported a record level of sales contracts. The CGS share price jumped 30% to 39 cents during lunch time trade when the All Ordinaries (Index:^AORD)...

Neuroscience technology company Cogstate (CGS), has achieved an additional $19.1 million of clinical trials sales contracts so far this quarter The total value of contracts executed since July 1st is $26.8 million, which is the best half y...

Neuroscience technology company Cogstate (ASX: CGS) revealed it has executed US$26.8 million (A$38.88 million) in clinical trial sales contracts for the 2020 financial year to date – making it the company’s best half year result on record....

Penny stocks may just sound penny but can possibly land the investor in a lifetime’s fortune. The penny stocks/shares in which you invest might not be as penny in terms of their return potential as it might simply sound. Here, we shall focu...

Last week it was former Hawthorn president Andrew Newbold who took a big leap of faith in his firm; this week it was former AFL commissioner Mike Fitzpatrick. He is on the board of Carnegie Clean Energy (ASX:CCE), which was finally recapita...

Getting traction has taken time. But for the likes of Cogstate (ASX:CGS) and Total Brain (ASX:TTB), which have developed online mental health programs, deals with partners boasting deep pockets have begun to flow. This is giving management...

Penny Stocks Penny stocks are those stocks that trade at a low price of less than $1. These stocks also have a small market cap and are speculative in nature. Trading in penny stocks involves a lot of risks. Thus, before making any investme...

Zelda Therapeutics Ltd (ASX: ZLD) Cannabis Group Zelda Therapeutics released its quarterly results for the three months ended 30 June 2019. The company reported a continued progress in its core clinical and preclinical programs and is in th...

In this week’s recap of substantial shareholders, IOOF and a UK hedge fund manager take a bet they’ll recoup their losses in Speedcast (ASX:SDA), Australian Ethical Investment buys a 16 per cent stake in Cogstate (ASX:CGS) and Taurus increa...